MX2009011495A - V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad. - Google Patents

V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.

Info

Publication number
MX2009011495A
MX2009011495A MX2009011495A MX2009011495A MX2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A MX 2009011495 A MX2009011495 A MX 2009011495A
Authority
MX
Mexico
Prior art keywords
cholerae
cholera toxin
hyperexpressing
recombinant cholera
immunogenicity
Prior art date
Application number
MX2009011495A
Other languages
English (en)
Inventor
Kenneth L Roland
Kevin P Killeen
Lawrence J Thomas
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of MX2009011495A publication Critical patent/MX2009011495A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se presentan composiciones inmunogénicas orales que imparten doble protección, contra Escherichia ccli que expresa la toxina lábil (LT) enterotoxigénica y contra Vibrio cholerae, con base en el suministro de antígeno toxina B de cólera recombinante por medio de vectores bacterianos vivos atenuados, derivados de Vibrio cholerae. Las composiciones tienen doble inmunogenicidad y retienen la capacidad para colonizar tejidos linfoides asociados a la mucosa gastrointestinal.
MX2009011495A 2007-04-24 2008-04-24 V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad. MX2009011495A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92612307P 2007-04-24 2007-04-24
PCT/US2008/005261 WO2008133926A1 (en) 2007-04-24 2008-04-24 V. cholerae hyperexpressing recombinant cholera toxin b subunit showing dual immunogenicity

Publications (1)

Publication Number Publication Date
MX2009011495A true MX2009011495A (es) 2010-02-15

Family

ID=39925978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011495A MX2009011495A (es) 2007-04-24 2008-04-24 V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.

Country Status (5)

Country Link
US (2) US8287855B2 (es)
CN (1) CN101730737B (es)
CA (1) CA2684742C (es)
MX (1) MX2009011495A (es)
WO (1) WO2008133926A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2684742C (en) * 2007-04-24 2014-07-08 Celldex Therapeutics, Inc. V. cholerae hyperexpressing recombinant cholera toxin b subunit showing dual immunogenicity
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381706B1 (en) 1987-10-07 1995-04-26 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
ATE242319T1 (de) * 1992-07-06 2003-06-15 Harvard College Deletionsmutanten als impfstoffe gegen cholera
US6203799B1 (en) 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
EP0832255B1 (en) * 1995-06-07 2005-12-14 Washington University Recombinant bacterial system with environmentally limited viability
JP4086945B2 (ja) * 1996-12-10 2008-05-14 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 非毒性Ｖ．Ｃｈｏｌｅｒａｅ株の単離法およびその株由来のコレラワクチンの製造法
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
CA2684742C (en) * 2007-04-24 2014-07-08 Celldex Therapeutics, Inc. V. cholerae hyperexpressing recombinant cholera toxin b subunit showing dual immunogenicity

Also Published As

Publication number Publication date
US8287855B2 (en) 2012-10-16
CA2684742C (en) 2014-07-08
US20100129396A1 (en) 2010-05-27
US20130122039A1 (en) 2013-05-16
CN101730737B (zh) 2016-06-01
WO2008133926A1 (en) 2008-11-06
CN101730737A (zh) 2010-06-09
CA2684742A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
CA2931146C (en) Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
Jazayeri et al. Recent advances in delivery of veterinary DNA vaccines against avian pathogens
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
MX2009006178A (es) Vacuna contra salmonela.
EP2620157A3 (en) Vaccine nanotechnology
Gayet et al. Vaccination against Salmonella infection: the mucosal way
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
EP4219566A3 (en) Recombinant rsv antigens
EP2105129A3 (en) Encapsulated Vaccines for the Oral Vaccination and Boostering of Fish and Other Animals
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
EP3725328A3 (en) Novel adjuvant compositions
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
WO2009103555A3 (en) Mucosal membrane receptor and uses thereof
WO2007116102A3 (en) Therapeutic composition and use
MX2023003169A (es) Composiciones de vacunas multivalentes y usos de las mismas.
MD20100029A2 (ro) Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) şi vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
WO2020039359A3 (en) Escherichia coli compositions and methods thereof
MX2009011495A (es) V cholerae que sobreexpresa la subunidad b de la toxina del colera recombinante y que presenta doble inmunogenicidad.
WO2009002372A3 (en) Prevention and treatment of gram negative, flagellated bacterial infections
Yunle et al. Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants—A review
WO2011100489A3 (en) Improved live bacterial vaccine safety
WO2011025344A3 (ko) 소의 병원성 대장균의 부착인자가 형질전환된 약독화 살모넬라균 변이주 및 이를 포함하는 소의 대장균증 및 살모넬라균증의 예방 및 치료용 백신조성물
WO2001089456A3 (en) Hybrid lt-a/ct-b holotoxin for use as an adjuvant
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
WO2009049013A3 (en) Cholera vaccines

Legal Events

Date Code Title Description
FG Grant or registration